Differential protein expressions in breast cancer between drug sensitive tissues and drug resistant tissues.
10.3969/j.issn.1672-7347.2013.02.007
- Author:
Wenjun YI
1
;
Jing PENG
;
Yajie ZHANG
;
Fenfen FU
;
Qiongyan ZOU
;
Yuanyuan TANG
Author Information
1. Department of Breast and Thyroid Surgery, Central South University, Changsha, China yiwenjun@csco.org.cn
- Publication Type:Journal Article
- MeSH:
Adult;
Aged;
Breast Neoplasms;
drug therapy;
genetics;
metabolism;
Carcinoma, Ductal, Breast;
drug therapy;
genetics;
metabolism;
Drug Resistance, Neoplasm;
genetics;
Female;
Gene Expression Profiling;
HSP27 Heat-Shock Proteins;
metabolism;
Humans;
Keratin-19;
metabolism;
Keratin-9;
metabolism;
Middle Aged;
Neoadjuvant Therapy;
Neoplasm Proteins;
metabolism;
Proteome;
metabolism;
Proteomics;
Thymidine Phosphorylase;
metabolism
- From:
Journal of Central South University(Medical Sciences)
2013;38(2):148-154
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the differential expression of the sensitive and resistant relative proteins in human breast cancer tissue.
METHODS:A drug sensitive group and a drug resistant group for chemotherapy in patients with breast cancer were selected through neoadjuvant. The differential protein expression in 2 groups was detected by proteomics techniques, and parts of differential proteins were identified by Western blot.
RESULTS:There were 13 differential proteins in the 2 groups, in which the expression of 3 proteins was up-regulated and 10 down-regulated. Seven proteins were identified by Western blot. The expression of keratin type I cytoskeletal 19 (KIC19), thymidine phosphorylase (TYPH) was upregulated, and the expression of heat shock protein 27 (HSP27), keratin type I cytoskeletal 9 (KIC9), collagen alpha-2(VI) (CO6A2), vimentin (VIME), and actin cytoplasmic 1 (ACTB) was down-regulated in the drug resistant group. There was significant difference between the 2 groups (P<0.01).
CONCLUSION:The expression of KIC19 and TYPH may be correlated with drug resistance in patients with breast cancer, and HSP27, KIC9, CO6A2, VIME, and ACTB may be correlated with drug sensitivity.
